Although the precise breakpoint locations and signatures of AR-GSRs are non-recurrent, the expression of COOH-terminally truncated AR-Vs with constitutive activity appears to be at least one recurrent functional outcome across prostate cancer cell lines, patient-derived xenografts and clinical tissues with high variant allele fractions of AR-GSRs. The gene discussed is AR; the disease is Familial prostate cancer.